Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma

Haematologica

Volumn 93, Issue 3, 2008, Pages 336-338

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; FLUDARABINE; MITOXANTRONE; PURINE DERIVATIVE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; METASTASIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHODGKIN LYMPHOMA; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; SHORT SURVEY; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

ACUTE DISEASE; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITALY; LEUKEMIA, MYELOID; LYMPHOMA, NON-HODGKIN; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOIMMUNOTHERAPY; RADIOTHERAPY; TRANSPLANTATION, AUTOLOGOUS; VIDARABINE;

EID: 40849126615     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12585     Document Type: Short Survey

References (26)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
2. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
3. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
4. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32:
5. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96.
6. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-8.
7. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75.
8. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80.
9. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
10. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
11. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-94.
12. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3128-35.
13. Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993;85:1932-7.
14. Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JD Jr. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 1996;14:565-71.
15. Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67:2002-9.
16. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, et al. Secondary malignancies after treatment for non-Hodgkin indolent lymphoma: a 16-year follow-up study. Haematologica 2008; 93:372-80.
17. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006;91:1546-50.
18. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573-5.
19. Friedberg JW. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:7789-91.
20. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285-92.
21. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-82.
22. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9.
23. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/ iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: fiveyear follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9.
24. Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19:1610-8.
25. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-7.
26. Friedberg JW. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica 2006;91: 1453-5.